Carotuximab, identified as TRC105 or DE-122, represents a unique antibody-drug conjugate ADC currently under investigation for treating various cancerous conditions. This distinct molecule binds to a unique antigen, https://alyshatcyz516573.blogdigy.com/carotuximab-trc105-de-122-a-deep-dive-65727336